Healthcare
Kamada Ltd.(KMDA)
Live Price
Offline$7.44
+3.19% today
1Y Change
-8.52%
Window
Jun 25, 2025 โ Jun 22, 2026
- Market Cap
- $470.00M
- Revenue Growth
- +21.4%
- EPS Growth
- +52.0%
- Dividend Yield
- 3.0%
Coverage: 248 bars ยท Jun 25, 2025 โ Jun 22, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Kamada Ltd. (KMDA) is a Healthcare stock with a market cap of $470.00M and listed on NASDAQ. The stock last traded around $7.44 and down 8.5% across the available one-year price window (Jun 25, 2025 โ Jun 22, 2026). Baseline metrics include revenue growth of +21.4%, EPS growth of +52.0%, a dividend yield of 3.0%. What stands out right now is revenue +21.4%, EPS +52.0%, free cash flow -54.1% with operating margin 14.5% and ROIC 6.8%. The dividend matters to the case here, with a current yield around 3.0%. Valuation is more restrained than many high-expectation growth names at P/E 23.3 and price/sales 2.6. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines KMDA price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+21.4% vs +7.6% peer median
Operating Margin
Below sector median
+14.5% vs +19.4% peer median
P/E
Below sector median
23.3 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 13, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +21.4% and EPS at +52.0%, with operating margin around 14.5%.
Shareholder return is still part of the story
The stock is still offering a dividend yield around 3.0%, which matters if the thesis depends on income as much as growth.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -0.7% over the next 5 trading days and finished higher after 2 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 13, 2026 | โ | +2.2% | +0.1% | -5.3% |
2026 Mar 11, 2026 | -33.3% | +1.6% | +0.5% | -0.5% |
2025 Nov 10, 2025 | -10.0% | +0.6% | -2.6% | -3.0% |
Benchmark Edge
KMDA vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
KMDA
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
KMDA Max Drawdown
-22.99%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for KMDA and SPY.
Company Overview
Kamada Ltd.
NASDAQ Global Select
Kamada Ltd. provides plasma-derived protein therapeutics. It operates in two segments, Proprietary Products and Distribution. The company offers KAMRAB/KEDRAB for prophylaxis of rabies disease; CYTOGAM for prophylaxis of cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplant; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; VARIZIG for post exposure prophylaxis of varicella; and GLASSIA for intravenous AATD. It also provides KamRho (D) IM for prophylaxis of hemolytic disease of newborns; KamRho (D) IV for immune thermobocytopunic purpura; and snake bite antiserum to treat snake bites by the vipera palaestinae and echis coloratus. In addition, the company distributes BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN for Allergic rhinitis and Urticaria; IVIG for immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for cytomegalovirus virus; RUCONEST for angioedema attacks; heparin sodium injection for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. Further, it offers IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis ; and ELIGARD for prostate cancer. The company markets its products through strategic partners in the United States, as well as through distributors internationally. Kamada Ltd. has strategic partnerships with Takeda Pharmaceuticals Company Limited; PARI GmbH; and Kedrion Biopharma. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.
- Leadership
- Amir London
- IPO Date
- May 31, 2013
- Employees
- 420
- Street Address
- 2 Holzman Street
- Mailing
- Rehovot, 7670402
- Region
- Rehovot, IL
- Reporting Currency
- USD
- Investor Line
- 972 8 940 6472
- Last Updated
- May 1, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 23.3
- EV/EBITDA
- 10.8
- Price/Sales
- 2.6
- Price/Book
- 1.8
Growth
- Revenue
- +21.4%
- EPS
- +52.0%
- Free Cash Flow
- -54.1%
Profitability
- Gross Margin
- 42.3%
- Operating Margin
- 14.5%
- Net Margin
- 11.2%
- ROE
- 7.7%
- ROIC
- 6.8%
Balance Sheet
- Debt/Equity
- 0.04
- Current Ratio
- 4.07
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.